Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Glaxo, Novartis, Roche, Lilly Invest in Aileron | Contract Pharma

What are you searching for?

Sign in
Breaking News

Glaxo, Novartis, Roche, Lilly Invest in Aileron

GlaxoSmithKline, Novartis, Roche, and Eli Lilly have joined forces to invest venture capital into Aileron Therapeutics, a biotech company based in Cambridge, MA that is using novel chemical structures to make a new class of medicines.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline, Novartis, Roche, and Eli Lilly have joined forces to invest venture capital into Aileron Therapeutics, a biotech company based in Cambridge, MA that is using novel chemical structures to make a new class of medicines. GSK, Novartis, Roche and Lilly are all investing in a $40 million fundraising by the company.

Aileron’s synthetically locked (or “stapled”) peptides, in theory, will be able to target biochemical pathways involved in cell function and disease that conventional drugs cannot reach. Aileron plans to use the funding to pay for advancing the first experimental products towards clinical trials in 2010. Potential treatment areas include cancer, and immune, metabolic and infectious diseases.

“We believe that stapled peptides could represent a ‘fourth estate’ in therapeutics, emerging as a major class akin to small molecules, antibodies and vaccines,” said Michael Diem, partner at SR One, GSK’s venture arm.

Other investors in the latest funding round include Excel Medical Ventures and Apple Tree Partners. In previous financings, Aileron has raised $20 million in funding.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics